nach oben

Erschienen in:

01.01.2016 | Urology - Original Paper

Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review

verfasst von: Shadi Al-Khalil, David Boothe, Trey Durdin, Sowmya Sunkara, Phillip Watkins, Shengping Yang, Allan Haynes, Werner de Riese

Erschienen in: International Urology and Nephrology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To study the interaction between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).

Methods

In this study, we performed a chart review of a cohort of 448 biopsy naive men. These men received a multi-core biopsy at our institution due to increased prostate-specific antigen (PSA) serum levels (>4 ng/ml) and/or suspicious findings on digital rectal examination in the years between 2008 and 2013. Utilizing PSA and transrectal ultrasound (TRUS) prostate volume, we obtained the PSA density (PSAD) for each individual. PSAD was calculated by dividing serum PSA concentration by TRUS prostate volume.

Results

Large prostates >65 g may secrete enough PSA to have a PSAD above the suggested cutoff of 0.15, yet 50 % patients have no histologic evidence of PCa, whereas prostates <35 g and an elevated PSAD of above 0.15 will have histologic evidence of PCa 70 % of the time.

Conclusions

These results suggest that BPH in large prostates may be protective of PCa. The interaction of the different prostate zones, in particular the transition zone and peripheral zone, may play a significant role in the phenomenon observed in this study. However, sampling error may introduce bias that 12–16 core biopsies in larger prostates may be more likely missing the cancer lesion.

Arai Y, Maeda H, Ishitoya S, Okubo K, Okada T, Aoki Y (1997) Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 158(3 Pt 1):861–864PubMedCrossRef

Ayala AG, Ro JY, Babaian R, Troncoso P, Greignon DJ (1989) The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13(1):21–27PubMedCrossRef

Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, Begin LR, Elhilali MM (1994) Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 43(1):44–51 (discussion 51-2) PubMedCrossRef

Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815–816PubMed

Bostwick DG, Cooner WH, Denis L et al (1992) The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70(Suppl 1):291–301PubMedCrossRef

Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ (1999) Prostate cancer detection: relation to prostate size. Urology 53:764–768PubMedCrossRef

Fralund M, Carlsson S, Stranne J, Aus G, Hugosson J (2012) The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of >3.0 ng/mL is an independent risk factor for prostate cancer: Results from the Gothenburg Randomized Screening Trial. BJUI 638–642

Freedland SJ, Isaacs WB, Platz EA et al (2005) Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 23:7546–7554PubMedCrossRef

Klotz L, Vesprini D, Loblaw A (2014) Long-term follow-up of a large active surveillance cohort. In: Abstract PD14-03/Prostate Cancer Localized II. Presented at the American Urological Association annual meeting on May 18, 2014, Orlando, FL

10.

Kopp RP, Freedland SJ, Parsons JK (2011) Associations of benign prostatic hyperplasia with prostate cancer: the debate continues. Eur Urol 60:699–700 (discussion 701–2) PubMedCrossRef

11.

Marks LS, Roehrborn CG, Wolford E, Wilson TH (2007) The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol 177(4):1408–1413PubMedCrossRef

12.

McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care. 12(5 Suppl):S122–S128PubMed

13.

Oh JJ et al (2013) Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy? Prostate 73(1):42–47PubMedCrossRef

14.

Ohori M, Dunn JK, Scardino PT (1995) Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 46:666–671PubMedCrossRef

15.

Powell IJ, Bock CH, Ruterbusch JJ, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white american men, and influences racial progression and mortality disparity. J Urol 183:1792–1797PubMedCrossRef

16.

SchenkJM Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM (2011) Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 173(12):1419–1428CrossRef

17.

Shariat SF, Roehrborn CG (2008) Using biopsy to detect prostate cancer. Rev Urol 10(4):262–280PubMedPubMedCentral

18.

Tubaro A, De Nunzio C, Mariani S, Trucchi A, Miano R, Vicentini C, Miano L (2010) Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. Urology 76:436–441PubMedCrossRef

19.

Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF (2003) The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 169(1):130–135PubMedCrossRef

20.

Web (2014) American Urological Association Symptom Score. http://www.urologyhealth.org/_media/_pdf/AUA%20Symptom%20Score.pdf

21.

Yu HJ, Lai MK (1998) The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer. Urology 51(5A Suppl.):125–130PubMedCrossRef

Titel: Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review
verfasst von: Shadi Al-Khalil
David Boothe
Trey Durdin
Sowmya Sunkara
Phillip Watkins
Shengping Yang
Allan Haynes
Werner de Riese
Publikationsdatum: 01.01.2016
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-015-1146-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review